Stockreport

Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF Phase III for recurrent/metastatic HPV-negative head and neck cancer, using a 1,500 mg pivotal dose with ORR as a potential accelerated approval endpoint and top-line da [Read more]